IN COLON CANCER a Dissertation by SATYA SREEHARI PATHI Su

Total Page:16

File Type:pdf, Size:1020Kb

IN COLON CANCER a Dissertation by SATYA SREEHARI PATHI Su MECHANISMS OF ACTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) IN COLON CANCER A Dissertation by SATYA SREEHARI PATHI Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY August 2012 Major Subject: Toxicology MECHANISMS OF ACTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) IN COLON CANCER A Dissertation by SATYA SREEHARI PATHI Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Stephen H. Safe Committee Members, Robert C. Burghardt Timothy Phillips Yanan Tian Interdisciplinary Faculty Chair of Toxicology, Weston Porter August 2012 Major Subject: Toxicology iii ABSTRACT Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Colon Cancer. (August 2012) Satya Sreehari Pathi, B.V.M., Acharya N. G. Ranga Agricultural University, India; M.S., Texas A&M University, Kingsville Chair of Advisory Committee: Dr. Stephen H. Safe Non-steroidal anti-inflammatory drugs (NSAIDs) and their NO derivatives (NO- NSAIDs), and synthetic analogs are highly effective as anticancer agents that exhibit relatively low toxicity compared to most clinically used drugs. However, the mechanisms of action for NSAIDs and NO-NSAIDs are not well defined and this has restricted their clinical applications and applications for combined therapies. Earlier studies from our laboratory reported that specificity protein (Sp) transcription factors (Sp1, Sp3 and Sp4) are overexpressed in several types of human cancers including colon cancer and many Sp-regulated genes are pro-oncogenic and individual targets for cancer chemotherapy. Based on published results showing that NSAIDs downregulate several putative Sp- regulated genes, we hypothesized that the anticancer properties of NSAIDs may be due, in part, to downregulation of Sp transcription factors. NSAIDs and nitro derivatives of NSAIDs have been investigated in colon cancer cells and in vivo xenograft models. Aspirin and TA induced apoptosis and decreased colon cancer cell growth and tumor growth in vivo and downregulated genes associated with cell growth, survival, and angiogenesis. Previous RNA interference studies in this laboratory have shown that many of these genes are regulated, in part, by Sp iv transcription factors Sp1, Sp3 and Sp4 that are overexpressed in colon and other cancer cell lines. Not surprisingly, these NSAIDs also decreased Sp1, Sp3 and Sp4 proteins and Sp-regulated gene products in colon cancer cells and this was due to caspase-dependent proteolysis of Sp1, Sp3 and Sp4. Aspirin-induced activation of caspases and degradation of Spproteins was due to sequestration of zinc and could be reversed by addition of zinc sulphate, whereas TA mediated induction of caspases was independent of zinc ions and is currently being investigated. GT-094 is a novel NO chimera-containing NSAID, which also inhibited colon cancer cell proliferation and induced apoptosis; these effects were accompanied by decreased mitochondrial membrane potential (MMP) and induction of reactive oxygen species (ROS), and were reversed after cotreatment with the antioxidant glutathione. GT-094 also downregulated Sp and Sp-dependent gene products and was due to decreased expression of microRNA-27a (miR-27a) and induction of ZBTB10, an Sp transcriptional repressor that is regulated by miR-27a in colon cancer cells. Moreover, the effects of GT-094 on Sp1, Sp3, Sp4, miR-27a and ZBTB10 were also inhibited by glutathione suggesting that the anticancer activity of GT-094 in colon cancer cells is due, in part, to ROS-dependent disruption of miR-27a:ZBTB10. The importance of ROS induction in targeting Sp transcription factors was also confirmed using pro-oxidants such as ascorbic acid, hydrogen peroxide and t-butyl hydroperoxide and similar results have been observed in collaborative studies with other ROS inducers in colon cancer cells. Many cancer cell lines and tumors exhibit addiction to non-oncogenes such as Sp1, Sp3 and Sp4 for maintaining the oncogenic phenotype and future research will focus on the mechanisms of ROS-mediated targeting of Sp transcription factors which represents a novel approach for cancer chemotherapy. v DEDICATION I dedicate my dissertation to my parents Pathi Satya Narayana Vara Prasad and Pathi Venkata Subbamma. They are my strength and without their support I would not stand here. My gratitude and my love to them are beyond words. vi ACKNOWLEDGEMENTS It‘s my pleasure to thank the many people who made this dissertation possible. Firstly, I would like to express my gratitude to Dr. Stephen Safe, the chair of my advisory committee, for giving me the precious opportunity to work with him and without him; I never would have made it through this challenge. I am very much thankful for his constant support, guidance, and encouragement, which allowed me to venture into new areas and grow as a researcher. He is very understanding, patient and a great person to work with and his precious suggestions will always be remembered. I would like to thank all my committee members, Dr. Robert Burghardt, Dr. Timothy Phillips and Dr. Yanan Tian, for their scholarly guidance and valuable suggestions during my doctoral program. I would like to thank my father and mother, Pathi Satya Narayana Varaprasad and Pathi Venkata Subbamma, for giving me courage and strength needed to achieve my goals. I am deeply grateful to my adorable wife, Mrs. Harika for her consistent support in our newly wedded life. She is awesome and with in short span of wedded life she made an impact in my life. I love her very much. My heartfelt thank to her for helping me in writing this dissertation. I also want to thank my brothers, Pathi Satya Srinivasulu and Pathi Satya Manohar, for their love and encouragement through all my endeavors. I must also, thank my sister-in-laws, Haritha and Vijaya and and my chirpy toddlers, Chinnu and Minnu. vii I would also like to mention the love and care from my mother-in-law Gundlapalli Padmavathi and my father-in-law Gundlapalli Venkateswra Prasad and brother-in-law, Gundlapalli Jagadeesh. I would like to extend my thanks to all Safe lab members Indira Jutooru and Gayathri Chadalapaka, Xi Li, Sandeep Sreevalsan, Vijaya lekshemi, Shane for their constant support and help during my research, and my special thanks to Sudhakar Chintarllapalli and Sabitha Papineni for helping me to join this lab. I also want to thank my dearest friends Subbu, Ram, Praveena and Radhika for their friendship. I also take this opportunity to thank Dr. Jagadeesh for being helpful and for his moral support. A special thanks to Lorna Safe, Kathy Mooney, and Kim Daniel. Finally I thank the almighty for providing me strength and courage to be successful in all my endeavors. viii TABLE OF CONTENTS Page ABSTRACT ........................................................................................................... iii DEDICATION ........................................................................................................ v ACKNOWLEDGEMENTS ...................................................................................... vi TABLE OF CONTENTS ......................................................................................... viii LIST OF FIGURES ................................................................................................ x LIST OF TABLES .................................................................................................. xiv CHAPTER I INTRODUCTION ............................................................................... 1 Cancer ......................................................................................... 1 Colon cancer ............................................................................... 14 Epigenetic changes in colon cancer ............................................. 29 Inflammation and colorectal cancer ............................................. 34 Diagnosis and staging of colorectal cancer .................................. 49 Treatment of colorectal cancer..................................................... 52 Mechanism based anticancer drugs ............................................ 56 Transcription factors as drug targets ............................................ 68 Specificity protein (Sp) transcription factors as drug targets ......... 74 NSAIDs as anti-cancer agents ..................................................... 85 NO-NSAIDs and cancer ............................................................... 100 Ascorbic acid and cancer ............................................................. 108 II ASPIRIN INHIBITS COLON CANCER CELL AND TUMOR GROWTH AND DOWNREGULATES SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS ................................... 116 Introduction .................................................................................. 116 Materials and methods ................................................................ 118 Results ........................................................................................ 123 Discussion ................................................................................... 137 ix CHAPTER Page III TOLFENAMIC ACID (TA) INHIBITS COLON CANCER CELL AND TUMOR GROWTH AND DOWNREGULATES SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS ............ 142 Introduction .................................................................................
Recommended publications
  • Identification of Novel Pathways That Promote Anoikis Through Genome-Wide Screens
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2016-10-14 Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens Victoria E. Pedanou University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Biology Commons, and the Cancer Biology Commons Repository Citation Pedanou VE. (2016). Identification of Novel Pathways that Promote Anoikis through Genome-wide Screens. GSBS Dissertations and Theses. https://doi.org/10.13028/M27G6D. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/889 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. i TITLE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences, Worcester in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY OCTOBER 14TH, 2016 CANCER BIOLOGY ii SIGNATURE PAGE IDENTIFICATION OF NOVEL PATHWAYS THAT PROMOTE ANOIKIS THROUGH GENOME-WIDE SCREENS A Dissertation Presented By VICTORIA ELIZABETH PEDANOU This work was undertaken in the Graduate School of Biomedical Sciences Cancer Biology The signature of the Thesis Advisor signifies validation of Dissertation content ___________________________ Michael R. Green, Thesis Advisor The signatures of the Dissertation Defense Committee signify completion and approval as to style and content of the Dissertation __________________________________ Eric H.
    [Show full text]
  • Supplementary Table 4
    Li et al. mir-30d in human cancer Table S4. The probe list down-regulated in MDA-MB-231 cells by mir-30d mimic transfection Gene Probe Gene symbol Description Row set 27758 8119801 ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 15497 8101675 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 18536 8158725 ABL1 c-abl oncogene 1, receptor tyrosine kinase 21232 8058591 ACADL acyl-Coenzyme A dehydrogenase, long chain 12466 7936028 ACTR1A ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) 18102 8056005 ACVR1 activin A receptor, type I 20790 8115490 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 15688 7979904 ADAM21 ADAM metallopeptidase domain 21 14937 8054254 AFF3 AF4/FMR2 family, member 3 23560 8121277 AIM1 absent in melanoma 1 20209 7921434 AIM2 absent in melanoma 2 19272 8136336 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 18013 7954777 ALG10 asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog (S. pombe) 30049 7954789 ALG10B asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog B (yeast) 28807 7962579 AMIGO2 adhesion molecule with Ig-like domain 2 5576 8112596 ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 23414 7922121 ANKRD36BL1 ankyrin repeat domain 36B-like 1 (pseudogene) 29782 8098246 ANXA10 annexin A10 22609 8030470 AP2A1 adaptor-related protein complex 2, alpha 1 subunit 14426 8107421 AP3S1 adaptor-related protein complex 3, sigma 1 subunit 12042 8099760 ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 30227 8059854 ARL4C ADP-ribosylation factor-like 4C 32785 8143766 ARP11 actin-related Arp11 6497 8052125 ASB3 ankyrin repeat and SOCS box-containing 3 24269 8128592 ATG5 ATG5 autophagy related 5 homolog (S.
    [Show full text]
  • Identification of Candidate Biomarkers and Pathways Associated with Type 1 Diabetes Mellitus Using Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.08.447531; this version posted June 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karnataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2021.06.08.447531; this version posted June 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Type 1 diabetes mellitus (T1DM) is a metabolic disorder for which the underlying molecular mechanisms remain largely unclear. This investigation aimed to elucidate essential candidate genes and pathways in T1DM by integrated bioinformatics analysis. In this study, differentially expressed genes (DEGs) were analyzed using DESeq2 of R package from GSE162689 of the Gene Expression Omnibus (GEO). Gene ontology (GO) enrichment analysis, REACTOME pathway enrichment analysis, and construction and analysis of protein-protein interaction (PPI) network, modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network, and validation of hub genes were then performed. A total of 952 DEGs (477 up regulated and 475 down regulated genes) were identified in T1DM. GO and REACTOME enrichment result results showed that DEGs mainly enriched in multicellular organism development, detection of stimulus, diseases of signal transduction by growth factor receptors and second messengers, and olfactory signaling pathway.
    [Show full text]
  • Target Gene Gene Description Validation Diana Miranda
    Supplemental Table S1. Mmu-miR-183-5p in silico predicted targets. TARGET GENE GENE DESCRIPTION VALIDATION DIANA MIRANDA MIRBRIDGE PICTAR PITA RNA22 TARGETSCAN TOTAL_HIT AP3M1 adaptor-related protein complex 3, mu 1 subunit V V V V V V V 7 BTG1 B-cell translocation gene 1, anti-proliferative V V V V V V V 7 CLCN3 chloride channel, voltage-sensitive 3 V V V V V V V 7 CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like V V V V V V V 7 DUSP10 dual specificity phosphatase 10 V V V V V V V 7 MAP3K4 mitogen-activated protein kinase kinase kinase 4 V V V V V V V 7 PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) V V V V V V V 7 PPP2R5C protein phosphatase 2, regulatory subunit B', gamma V V V V V V V 7 PTPN4 protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) V V V V V V V 7 EZR ezrin V V V V V V 6 FOXO1 forkhead box O1 V V V V V V 6 ANKRD13C ankyrin repeat domain 13C V V V V V V 6 ARHGAP6 Rho GTPase activating protein 6 V V V V V V 6 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 V V V V V V 6 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like V V V V V V 6 BRMS1L breast cancer metastasis-suppressor 1-like V V V V V V 6 CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) V V V V V V 6 CTDSP1 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 1 V V V V V V 6 DCX doublecortin V V V V V V 6 ENAH enabled homolog (Drosophila) V V V V V V 6 EPHA4 EPH receptor A4 V V V V V V 6 FOXP1 forkhead box P1 V
    [Show full text]
  • Supp Data.Pdf
    Supplementary Methods Verhaak sub-classification The Verhaak called tumor subtype was assigned as determined in the Verhaak et al. manuscript, for those TCGA tumors that were included at the time. TCGA data for expression (Affymetrix platform, level 1) and methylation (Infinium platform level 3) were downloaded from the TCGA portal on 09/29/2011. Affymetrix data were processed using R and Biocondutor with a RMA algorithm using quantile normalization and custom CDF. Level 3 methylation data has already been processed and converted to a beta-value. The genes that make up the signature for each of the 4 Verhaak groups (i.e. Proneural, Neural, Mesenchymal, and Classical) were downloaded. For each tumor, the averaged expression of the 4 genes signatures was calculated generating 4 ‘metagene’ scores, one for each subtype, (Colman et al.2010) for every tumor. Then each subtype metagene score was z-score corrected to allow comparison among the 4 metagenes. Finally, for each tumor the subtype with the highest metagene z-score among the four was used to assign subtype. Thus by this method, a tumor is assigned to the group to which it has the strongest expression signature. The shortcoming is that if a tumor has a ‘dual personality’ – for instance has strong expression of both classical and mesenchymal signature genes, there is some arbitrariness to the tumor’s assignment. Western Blot Analysis and cell fractionation Western blot analysis was performed using standard protocols. To determine protein expression we used the following antibodies: TAZ (Sigma and BD Biosciences), YAP (Santa Cruz Biotechnology), CD44 (Cell Signaling), FN1 (BD Biosciences), TEAD1, TEAD2, TEAD3, TEAD4 (Santa Cruz Biotechnology), MST1, p-MST1, MOB1, LATS1, LATS2, 14-3-3-, 1 ACTG2, (Cell Signaling), p-LATS1/2 (Abcam), Flag (Sigma Aldrich), Actin (Calbiochem), CAV2 (BD Biosciences), CTGF (Santa Cruz), RUNX2 (Sigma Aldrich), Cylin A, Cyclin E, Cyclin B1, p-cdk1, p-cdk4 (Cell Signaling Technologies).
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]
  • Cell Cycle Arrest Through Indirect Transcriptional Repression by P53: I Have a DREAM
    Cell Death and Differentiation (2018) 25, 114–132 Official journal of the Cell Death Differentiation Association OPEN www.nature.com/cdd Review Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM Kurt Engeland1 Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV.Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia.
    [Show full text]
  • Systems Genetics Identifies a Role for Cacna2d1 Regulation in Elevated
    Supplementary Dataset 1: Gene set enrichment analysis (GSEA) input Gene Symbol Gene name Score Cacna2d1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 1 Pten phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 0.8113829 Rora RAR-related orphan receptor A 0.7830256 Nfia nuclear factor I/A 0.77796155 Plxna2 plexin A2 0.7689365 Rwdd4a RWD domain containing 4A 0.75700486 Znf608 zinc finger protein 608 0.7334024 Huwe1 HECT, UBA and WWE domain containing 1 0.73015225 Prkg1 protein kinase, cGMP-dependent, type I 0.7254574 Rab39b RAB39B, member RAS oncogene family 0.71763426 St3gal2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 0.70345706 Lpgat1 lysophosphatidylglycerol acyltransferase 1 0.7029922 potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia Kcna1 0.7010396 with myokymia) Ppp2ca protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 0.69497764 Maoa monoamine oxidase A 0.6936078 Socs6 suppressor of cytokine signaling 6 0.6922545 Abcc5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 0.6845195 Hspa4 heat shock 70kDa protein 4 0.6812371 Dctn4 dynactin 4 (p62) 0.68075943 Lats2 LATS, large tumor suppressor, homolog 2 (Drosophila) 0.67761165 Lin7a lin-7 homolog A (C. elegans) 0.673076 Itga9 integrin, alpha 9 0.6707624 Isoc1 isochorismatase domain containing 1 0.6701377 Cyfip2 cytoplasmic FMR1 interacting protein 2 0.6698394 Asip agouti signaling protein, nonagouti homolog (mouse) 0.6682124 Trpm7 transient receptor potential cation channel, subfamily M,
    [Show full text]
  • Differentially Expressed Genes Using Genomic Expression Profiles An
    Downloaded from genome.cshlp.org on July 13, 2011 - Published by Cold Spring Harbor Laboratory Press An Efficient and Robust Statistical Modeling Approach to Discover Differentially Expressed Genes Using Genomic Expression Profiles Jeffrey G. Thomas, James M. Olson, Stephen J. Tapscott, et al. Genome Res. 2001 11: 1227-1236 Access the most recent version at doi:10.1101/gr.165101 References This article cites 78 articles, 33 of which can be accessed free at: http://genome.cshlp.org/content/11/7/1227.full.html#ref-list-1 Article cited in: http://genome.cshlp.org/content/11/7/1227.full.html#related-urls Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article or click here To subscribe to Genome Research go to: http://genome.cshlp.org/subscriptions Cold Spring Harbor Laboratory Press Downloaded from genome.cshlp.org on July 13, 2011 - Published by Cold Spring Harbor Laboratory Press Methods An Efficient and Robust Statistical Modeling Approach to Discover Differentially Expressed Genes Using Genomic Expression Profiles Jeffrey G. Thomas,1 James M. Olson,2 Stephen J. Tapscott,2 and Lue Ping Zhao1,3 1Division of Public Health Sciences and 2Division of Molecular Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA We have developed a statistical regression modeling approach to discover genes that are differentially expressed between two predefined sample groups in DNA microarray experiments. Our model is based on well-defined assumptions, uses rigorous and well-characterized statistical measures, and accounts for the heterogeneity and genomic complexity of the data.
    [Show full text]
  • Supplementary Figure S1 A
    Supplementary Figure S1 A B C 1 4 1 3 1 2 1 2 1 0 1 1 (Normalized signal values)] 2 (Normalized signal values) (Normalized 8 2 10 Log 6 AFFX-BioC AFFX-BioB AFFX-BioDn AFFX-CreX hDFs [Log 6 8 10 12 14 hOFs [Log2 (Normalized signal values)] Supplementary Figure S2 GLYCOLYSIS PENTOSE-PHOSPHATE PATHWAY Glucose Purine/pyrimidine Glucose-6-phosphate metabolism AMINO ACID Fluctose-6-phosphate AMPK METABOLISM TIGAR PFKFB2 methylgloxal GloI Ser, Gly, Thr Glyceraldehyde-3-phosphate ALDH Lactate PYRUVATE LDH METABOLISM acetic acid Ethanol Pyruvate GLYCOSPHINGOLIPID NADH BIOSYNTHESIS Ala, Cys DLD PDH PDK3 DLAT Fatty acid Lys, Trp, Leu, Acetyl CoA ACAT2 Ile, Tyr, Phe β-OXIDATION ACACA Citrate Asp, Asn Citrate Acetyl CoA Oxaloacetate Isocitrate MDH1 IDH1 Glu, Gln, His, ME2 TCA Pro, Arg 2-Oxoglutarate MDH1 CYCLE Pyruvate Malate ME2 GLUTAMINOLYSIS FH Succinyl-CoA Fumalate SUCLA2 Tyr, Phe Var, Ile, Met Supplementary Figure S3 Entrez Gene Symbol Gene Name hODs hDFs hOF-iPSCs GeneID 644 BLVRA biliverdin reductase A 223.9 259.3 253.0 3162 HMOX1 heme oxygenase 1 1474.2 2698.0 452.3 9365 KL klotho 54.1 44.8 36.5 nicotinamide 10135 NAMPT 827.7 626.2 2999.8 phosphoribosyltransferase nuclear factor (erythroid- 4780 NFE2L2 2134.5 1331.7 1006.2 derived 2) related factor 2 peroxisome proliferator- 5467 PPARD 1534.6 1352.9 330.8 activated receptor delta peroxisome proliferator- 5468 PPARG 524.4 100.8 63.0 activated receptor gamma 5621 PRNP prion protein 4059.0 3134.1 1065.5 5925 RB1 retinoblastoma 1 882.9 805.8 739.3 23411 SIRT1 sirtuin 1 231.5 216.8 1676.0 7157 TP53
    [Show full text]
  • Molecular Characterization and Generation of Sp2 Gene Targeted Mice
    Transcription factor Sp2: Molecular characterization and generation of Sp2 gene targeted mice Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) dem Fachbereich Biologie der Philipps Universität Marburg vorgelegt von Frank Baur aus Kirchheim/Teck Marburg, 2005 Vom Fachbereich Biologie der Philipps-Universität Marburg als Dissertation angenommen am: 15.08.2005 Erstgutachter: Prof. Dr. Renate Renkawitz-Pohl Zweitgutachter: Prof. Dr. Guntram Suske Tag der mündlichen Prüfung am: 15.09.2005 Contents Zusammenfassung I Summary III 1. Introduction 1 1.1 Regulation of gene expression 1 1.2 Transcription factors 3 1.3 The Sp/XKLF super-family of transcription factors 4 1.4 The Sp family of transcription factors: protein structure and function 8 1.5 Generation of transgenic mice by “gene targeting” 15 1.6 Thesis aims 19 2. Materials and methods 21 2.1 Materials 21 2.1.1 Laboratory materials and devices 21 2.1.2 Chemicals 21 2.1.3 General solutions 21 2.1.4 Culture media 22 2.1.4.1 Media to culture bacteria 22 2.1.4.2 Media to culture eukaryotic cells 22 2.1.5 Restriction enzymes and DNA-modifying enzymes 23 2.1.6 Antibiotics 23 2.1.7 Antibodies 23 2.1.8 Radioactive substances 24 2.1.9 Oligonucleotides 24 2.1.9.1 Oligonucleotides to generate Sp2 deletion mutants 24 2.1.9.2 Oligonucleotides for Electrophoretic Mobility Shift Assays 25 2.1.9.3 Oligonucleotides for RT-PCR, Southern Blot probes and cosmid library screen (RZPD) 25 2.1.9.4 Oligonucleotides for loxP site generation and PCR amplifi- cation of Sp2 genomic
    [Show full text]